S3446 Use of Proton Pump Inhibitors Is Not With the Risk of Diabetes Mellitus in North America? A Meta-Analysis

Abstract

Introduction: Previous reports showed that the use of proton pump inhibitor (PPI) might reduce the risk of diabetes mellitus. In North America, diabetes is one of the common diseases causing a great burden to health care, while PPI is also one of the most commonly used medications in North America. Therefore, this study was conducted to explore whether the use of PPI reduces the risk of diabetes mellitus for North American populations. Methods: A systematic literature search in Web of Science, Embase, PubMed, Cochrane Library, CNKI (China National Knowledge Infrastructure), CBM (China Biomedical Database), the VIP (Chinese), and Wanfang (Chinese) as conducted to identify eligible studies up to February 2021. All statistical analysis was performed using STATA 15.1. statistical software (Stata Corp., College Station, TX). Hazard ratios (HRs) with 95% confidence intervals (CI) were pooled through random-effect or fixed-effect model, depending on the heterogeneity which was evaluated through the Q test and I-squared statistic. Sensitivity analysis and publication bias assessment were also conducted. Results: Five studies were included. The use of PPI use was not associated with the change of diabetes mellitus risk (pooled HR = 1.06, 95% CI = 0.90–1.26, I2 = 92.9%). Sensitivity analysis by omitting one study at a time suggested the results were relatively stable. No publication bias was detected based on Egger's test (P = 0.896). Conclusion: The use of PPI is not associated with a change in the risk of diabetes mellitus for people in North America. However, further analysis based on different populations and geographic locations is still needed for more comprehensive evidence.Figure 1.: A) Forest Plot; B) Egger's test.Table 1.: Sensitive analysis by omitting one study at a time.